Literature DB >> 9232434

Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design.

P W Parren1, M C Gauduin, R A Koup, P Poignard, P Fisicaro, D R Burton, Q J Sattentau.   

Abstract

Understanding the antibody response in HIV-1 infection is important to vaccine design. We have studied the antibody response to HIV-1 envelope at the molecular level and determined the characteristics of neutralizing and non-neutralizing antibodies. These antibodies were isolated from phage display libraries prepared from long-term seropositive asymptomatic individuals. The HIV-1 envelope is presented to the immune system in several antigenically distinct configurations: unprocessed gp160, gp120 and gp41 subunits and native envelope, each of which may be important in eliciting an antibody response in HIV-1 infection. The antibodies tested characteristically had poor affinities for native envelope as expressed on the surface of virions or infected cells, but had high affinities against non-native forms of HIV-1 envelope (viral debris). An exceptionally potent neutralizing antibody in contrast, bound native envelope with equivalent or somewhat higher affinity than this. This indicates that the antibody response in HIV-1 infection is principally elicited by viral debris rather than virions, and that these antibodies bind and neutralize viruses sub-optimally. Potential vaccines should be designed to elicit responses against native envelope.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9232434     DOI: 10.1016/s0165-2478(97)00043-6

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  26 in total

1.  Minimal incidence of serum antibodies reactive with intact primary isolate virions in human immunodeficiency virus type 1-infected individuals.

Authors:  L A Cavacini; J E Peterson; E Nappi; M Duval; R Goldstein; K Mayer; M R Posner
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

2.  Conformational Engineering of HIV-1 Env Based on Mutational Tolerance in the CD4 and PG16 Bound States.

Authors:  Jeremiah D Heredia; Jihye Park; Hannah Choi; Kevin S Gill; Erik Procko
Journal:  J Virol       Date:  2019-05-15       Impact factor: 5.103

3.  Glycosylation of the core of the HIV-1 envelope subunit protein gp120 is not required for native trimer formation or viral infectivity.

Authors:  Ujjwal Rathore; Piyali Saha; Sannula Kesavardhana; Aditya Arun Kumar; Rohini Datta; Sivasankar Devanarayanan; Raksha Das; John R Mascola; Raghavan Varadarajan
Journal:  J Biol Chem       Date:  2017-04-26       Impact factor: 5.157

4.  Conformation-dependent recognition of HIV gp120 by designed ankyrin repeat proteins provides access to novel HIV entry inhibitors.

Authors:  Axel Mann; Nikolas Friedrich; Anders Krarup; Jacqueline Weber; Emanuel Stiegeler; Birgit Dreier; Pavel Pugach; Melissa Robbiani; Tina Riedel; Kerstin Moehle; John A Robinson; Peter Rusert; Andreas Plückthun; Alexandra Trkola
Journal:  J Virol       Date:  2013-03-13       Impact factor: 5.103

5.  Polysaccharide mimicry of the epitope of the broadly neutralizing anti-HIV antibody, 2G12, induces enhanced antibody responses to self oligomannose glycans.

Authors:  D Cameron Dunlop; Camille Bonomelli; Fatma Mansab; Snezana Vasiljevic; Katie J Doores; Mark R Wormald; Angelina S Palma; Ten Feizi; David J Harvey; Raymond A Dwek; Max Crispin; Christopher N Scanlan
Journal:  Glycobiology       Date:  2010-02-24       Impact factor: 4.313

6.  Stoichiometry of envelope glycoprotein trimers in the entry of human immunodeficiency virus type 1.

Authors:  Xinzhen Yang; Svetla Kurteva; Xinping Ren; Sandra Lee; Joseph Sodroski
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

7.  Additive effects characterize the interaction of antibodies involved in neutralization of the primary dualtropic human immunodeficiency virus type 1 isolate 89.6.

Authors:  F Verrier; A Nádas; M K Gorny; S Zolla-Pazner
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

8.  Generation of neutralizing activity against human immunodeficiency virus type 1 in serum by antibody gene transfer.

Authors:  Anne D Lewis; Ruju Chen; David C Montefiori; Philip R Johnson; K Reed Clark
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

9.  Increased neutralization sensitivity of recently emerged CXCR4-using human immunodeficiency virus type 1 strains compared to coexisting CCR5-using variants from the same patient.

Authors:  Evelien M Bunnik; Esther D Quakkelaar; Ad C van Nuenen; Brigitte Boeser-Nunnink; Hanneke Schuitemaker
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

10.  Enzymatic removal of mannose moieties can increase the immune response to HIV-1 gp120 in vivo.

Authors:  Kaustuv Banerjee; Sofija Andjelic; Per Johan Klasse; Yun Kang; Rogier W Sanders; Elizabeth Michael; Robert J Durso; Thomas J Ketas; William C Olson; John P Moore
Journal:  Virology       Date:  2009-05-02       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.